# Where full-length human IGF-1 fits in the growth hormone pathway

- Article ID: research-193
- Product: IGF-1 Human (igf-1-human-625)
- Canonical page: https://heritagebiolabs.com/research-library/articles/193-where-full-length-human-igf-1-fits-in-the-growth-hormone-pathway
- Product collection: https://heritagebiolabs.com/research-library/products/igf-1-human
- Product page: https://heritagebiolabs.com/product/igf-1-human-625
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2006, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptide bonds join amino acids into short chains called peptides. Longer chains can fold into hormones that carry signals between tissues. Human insulin-like growth factor 1 (IGF-1) is a 70-residue hormone with three internal disulfide bonds, which help hold the folded chain together. Mecasermin is the recombinant pharmaceutical form. How does providing IGF-1 differ from providing the growth hormone that ordinarily stimulates it? [1]

Growth hormone can tell the liver and other tissues to produce IGF-1. IGF-1 then activates its own receptor in target tissues and helps support processes involved in growth, including activity at the growth plates of bones. If the body's ability to respond to growth hormone is impaired, normal or elevated growth hormone can coexist with very low IGF-1. The U.S. prescribing information for mecasermin describes use in children at least two years old with severe primary IGF-1 deficiency, or with growth hormone gene deletion and neutralizing antibodies to growth hormone. [1]

Older primary evidence addressed how children with severe IGF-1 deficiency due to growth hormone insensitivity grew during treatment with recombinant IGF-1. In a long-term study, average height velocity increased in the first treatment year compared with pretreatment velocity. In later years growth was slower than in the first year, although the investigators reported increases over pretreatment velocity for several years. This shows the importance of measuring growth repeatedly instead of assuming that the first-year pace continues. [2]

No newer primary study of that foundational treatment comparison was identified for this article. The older trial was predominantly open-label and studied children with a defined, severe growth disorder. The indication and evidence concern full-length recombinant human IGF-1 in that setting. A low measurement on its own does not identify the reason the level is low, and the prescribing information distinguishes severe primary deficiency from low IGF-1 due to other causes. [1, 2]

## Sources

1. Eton Pharmaceuticals, Inc. INCRELEX (mecasermin) injection, for subcutaneous use. DailyMed (label effective 2026-05-18). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce>
2. Chernausek SD et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. Journal of Clinical Endocrinology & Metabolism (publication 2006-12-27). <https://pubmed.ncbi.nlm.nih.gov/17192294/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 039 - IGF-1 Human and IGF-1 DES 1 3.docx; article 193; content SHA-256 bbe3bbbfd3cf7cdc3bc3dc46fa13cb79d53445a5288047d7ddc9c9d5095b0fbd.
